US Stock MarketDetailed Quotes

CGON CG Oncology

Watchlist
  • 21.700
  • -6.480-23.00%
Close May 6 16:00 ET
  • 22.760
  • +1.060+4.88%
Pre 08:03 ET
1.65BMarket Cap-18.77P/E (TTM)

CG Oncology Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
458.33%1.14M
45,500.00%456K
377.78%43K
111K
172.68%529K
6.81%204K
1K
9K
0
194K
Operating revenue
458.33%1.14M
45,500.00%456K
377.78%43K
--111K
172.68%529K
6.81%204K
--1K
--9K
--0
--194K
Cost of revenue
Gross profit
Operating expense
108.08%115.81M
98.93%38.51M
101.67%28.34M
110.64%25.96M
131.95%23M
57.05%55.65M
107.79%19.36M
14.05M
12.33M
9.92M
Selling and administrative expenses
240.40%33.7M
288.10%11.71M
276.18%8.72M
200.48%7.49M
179.21%5.79M
54.51%9.9M
82.02%3.02M
--2.32M
--2.49M
--2.07M
-General and administrative expense
240.40%33.7M
288.10%11.71M
276.18%8.72M
200.48%7.49M
179.21%5.79M
54.51%9.9M
82.02%3.02M
--2.32M
--2.49M
--2.07M
Research and development costs
79.45%82.1M
64.01%26.8M
67.21%19.62M
87.86%18.47M
119.46%17.21M
57.61%45.75M
113.37%16.34M
--11.74M
--9.83M
--7.84M
Operating profit
-106.80%-114.67M
-96.58%-38.05M
-101.49%-28.3M
-109.74%-25.85M
-131.14%-22.47M
-57.32%-55.45M
-107.78%-19.36M
-14.04M
-12.33M
-9.72M
Net non-operating interest income expense
285.63%26.62M
122.72%6.25M
245.69%7.89M
800.52%6.94M
430.21%5.55M
690,500.00%6.9M
208.13%2.8M
2.28M
771K
1.05M
Non-operating interest income
285.63%26.62M
122.72%6.25M
245.69%7.89M
800.52%6.94M
430.21%5.55M
--6.9M
--2.8M
--2.28M
--771K
--1.05M
Other net income (expense)
104.84%3K
250.00%6K
75.00%-2K
113.79%8K
-212.50%-9K
68.37%-62K
-130.77%-4K
-8K
-58K
8K
Other non- operating income (expenses)
104.84%3K
250.00%6K
75.00%-2K
113.79%8K
-212.50%-9K
68.37%-62K
-130.77%-4K
---8K
---58K
--8K
Income before tax
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.36%-16.93M
-37.14%-48.61M
-97.27%-16.56M
-11.77M
-11.61M
-8.67M
Income tax
Net income
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.36%-16.93M
-37.14%-48.61M
-97.27%-16.56M
-11.77M
-11.61M
-8.67M
Net income continuous Operations
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.36%-16.93M
-37.14%-48.61M
-97.27%-16.56M
---11.77M
---11.61M
---8.67M
Minority interest income
Net income attributable to the parent company
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.36%-16.93M
-37.14%-48.61M
-97.27%-16.56M
-11.77M
-11.61M
-8.67M
Preferred stock dividends
129.97%19.19M
57.43%5.94M
5.75M
3.78M
3.73M
Other preferred stock dividends
Net income attributable to common stockholders
-29.85%-88.04M
-41.39%-31.8M
-16.51%-20.41M
-22.83%-18.9M
-36.54%-16.93M
-54.83%-67.8M
-84.92%-22.49M
-17.51M
-15.39M
-12.4M
Basic earnings per share
-32.03%-1.41
-35.49%-0.48
-8.74%-0.3
-15.51%-0.28
87.43%-0.36
90.88%-1.068
87.38%-0.3543
-0.2759
-0.2424
-2.8634
Diluted earnings per share
-32.03%-1.41
-35.49%-0.48
-8.74%-0.3
-15.51%-0.28
87.43%-0.36
90.88%-1.068
87.38%-0.3543
-0.2759
-0.2424
-2.8634
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 458.33%1.14M45,500.00%456K377.78%43K111K172.68%529K6.81%204K1K9K0194K
Operating revenue 458.33%1.14M45,500.00%456K377.78%43K--111K172.68%529K6.81%204K--1K--9K--0--194K
Cost of revenue
Gross profit
Operating expense 108.08%115.81M98.93%38.51M101.67%28.34M110.64%25.96M131.95%23M57.05%55.65M107.79%19.36M14.05M12.33M9.92M
Selling and administrative expenses 240.40%33.7M288.10%11.71M276.18%8.72M200.48%7.49M179.21%5.79M54.51%9.9M82.02%3.02M--2.32M--2.49M--2.07M
-General and administrative expense 240.40%33.7M288.10%11.71M276.18%8.72M200.48%7.49M179.21%5.79M54.51%9.9M82.02%3.02M--2.32M--2.49M--2.07M
Research and development costs 79.45%82.1M64.01%26.8M67.21%19.62M87.86%18.47M119.46%17.21M57.61%45.75M113.37%16.34M--11.74M--9.83M--7.84M
Operating profit -106.80%-114.67M-96.58%-38.05M-101.49%-28.3M-109.74%-25.85M-131.14%-22.47M-57.32%-55.45M-107.78%-19.36M-14.04M-12.33M-9.72M
Net non-operating interest income expense 285.63%26.62M122.72%6.25M245.69%7.89M800.52%6.94M430.21%5.55M690,500.00%6.9M208.13%2.8M2.28M771K1.05M
Non-operating interest income 285.63%26.62M122.72%6.25M245.69%7.89M800.52%6.94M430.21%5.55M--6.9M--2.8M--2.28M--771K--1.05M
Other net income (expense) 104.84%3K250.00%6K75.00%-2K113.79%8K-212.50%-9K68.37%-62K-130.77%-4K-8K-58K8K
Other non- operating income (expenses) 104.84%3K250.00%6K75.00%-2K113.79%8K-212.50%-9K68.37%-62K-130.77%-4K---8K---58K--8K
Income before tax -81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.36%-16.93M-37.14%-48.61M-97.27%-16.56M-11.77M-11.61M-8.67M
Income tax
Net income -81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.36%-16.93M-37.14%-48.61M-97.27%-16.56M-11.77M-11.61M-8.67M
Net income continuous Operations -81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.36%-16.93M-37.14%-48.61M-97.27%-16.56M---11.77M---11.61M---8.67M
Minority interest income
Net income attributable to the parent company -81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.36%-16.93M-37.14%-48.61M-97.27%-16.56M-11.77M-11.61M-8.67M
Preferred stock dividends 129.97%19.19M57.43%5.94M5.75M3.78M3.73M
Other preferred stock dividends
Net income attributable to common stockholders -29.85%-88.04M-41.39%-31.8M-16.51%-20.41M-22.83%-18.9M-36.54%-16.93M-54.83%-67.8M-84.92%-22.49M-17.51M-15.39M-12.4M
Basic earnings per share -32.03%-1.41-35.49%-0.48-8.74%-0.3-15.51%-0.2887.43%-0.3690.88%-1.06887.38%-0.3543-0.2759-0.2424-2.8634
Diluted earnings per share -32.03%-1.41-35.49%-0.48-8.74%-0.3-15.51%-0.2887.43%-0.3690.88%-1.06887.38%-0.3543-0.2759-0.2424-2.8634
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
JINGHAO MEDICAL
872925
+29.96%
TONGYI AEROSPACE
871642
+25.11%
ESKONJAC
839273
+21.20%
4
Jiangsu Olive Sensors High-Tech
300507
+20.05%
5
Jing-Jin Electric Technologies
688280
+20.05%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.